Articles Tagged 'Biopharma'

Endpoints News: Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA

STAT News: Roche partners with Arrakis Therapeutics to develop drugs that target RNA

FierceBiotech: Biotech Arrakis, Roche team up on RNA-targeting drugs in $190M deal

San Francisco Business Times: "Say it" - Nina Kjellson, Amy DuRoss and Gail Maderis on the barriers to funding women's health issues

BioCentury: Beyond PROTACs and the proteasome - broadening the TAC toolbox

CNBC: These start-ups are racing to help doctors detect cancer early with a simple blood test

Endpoints News: RA Capital, Canaan help infuse $50M into Alta-incubated biotech battling acquired resistance to TKIs

BioCentury: Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

FierceBiotech: Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise

Endpoints News: Canaan backs Pathios' search for small molecule drugs that hit 'orphan' GCPR

FierceBiotech: Canaan Partners promotes Julie Grant to general partner

Xconomy: With $9.5M, Intrepida Bio launches to target pancreatic cancer & more

FierceBiotech: Nocion Therapeutics named to Fierce 15

WoVen Podcast: Working with grit (and a patient's perspective) in women’s health - A conversation with Gail Maderis

FierceBiotech: A personalized CAR-T to attack every solid tumor? PACT Pharma has a plan

MedCityNews: Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study

Wired: These protein picker-uppers keep your cells clean and healthy

WoVen Podcast: Crafting success (and balance) in venture - A conversation with Wende Hutton

Endpoints News: Bayer enlists Arvinas on two-pronged protein degradation effort, foraying into agtech

Welcome Nils Lonberg

Tim Shannon in BioCentury: Making orphan drug prices work for society

Endpoints News: Four biotechs, including NextCure, haul in $303M+ from a fresh burst of IPOs

Business Insider: Scientists are working on cancer treatments that attack the disease's 'Holy Grail"

STAT News: Nils Lonberg, the entrepreneur behind the cancer immunotherapy revolution

STAT News: Arrakis' lofty goal: Kill cancer with pills that target RNA instead of proteins

FierceBiotech: Nocion launches with $27M and 'charged drugs' to selectively target pain

Business Insider: Nocion raises $27M to make a new kind of painkiller as the race to replace opioids heats up

STAT News: How one company, Nocion, thinks unraveling cough can provide a new way to treat pain

Julie Grant: Announcing Nocion Therapeutics, a novel approach to neurogenic inflammation

Nature: Protein-slaying drugs could be the next blockbuster therapies

Nature Reviews: First targeted protein degrader, developed by Arvinas, hits the clinic

BioCentury: Wende Hutton on mapping microbiome manufacturing

Endpoints News: Canaan leaps into UK biotech, co-leading $14M Series A for upstart Grey Wolf

Business Insider: Wende Hutton and top VCs give their best 2019 predictions for healthcare

SF Business Times: Antiva CEO draws on personal experience to fuel drug development

Nasdaq: Cancer biotech Arvinas prices upsized IPO at $16

Business Insider: Julie Grant named 40-and-under Silicon Valley biotech investing star

STAT News: Antiva tried to drum up interest for a much-needed drug. Many men didn’t get it

Nina Kjellson: "Jumping together" to move the field of personalized cancer therapy

BioCentury: Why GV and Canaan backed PACT Pharma's hyperpersonalized cancer approach

Endpoints News: Brent Aherns weights in on FDA's new reimbursement idea for antibiotics

Tim Shannon: More hope for cystic fibrosis treatment, and still more to do

Endpoints: Virtual biotech Antiva sets out on a big R&D quest, armed with a $22 million round for an HPV therapy

Scientific American: New thalidomide-like therapy hijacks cells’ trash-disposal system

Fierce Biotech: Mackay’s Rallybio rare disease startup raises $37M in first funding round

Nina Kjellson: Practical tips from two male biotech CEOs who are leaning in

IDEAYA & the Next Frontier in Synthetic Lethality

Business Insider: Wende Hutton shares her best career advice